Vir Biotechnology
61 hedge funds and large institutions have $1.3B invested in Vir Biotechnology in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 6 closing their positions.
383% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 6
105% more capital inflows, than outflows
Capital inflows: $71.8M | Capital outflows: $35M
104% more call options, than puts
Call options by funds: $699K | Put options by funds: $342K
61% more funds holding
Funds holding: 38 → 61 (+23)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
1.13% more ownership
Funds ownership: 33.36% → 34.48% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.27M |
| 2 |
BlackRock
New York
|
+$4.48M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$2.98M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.47M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICP
Indus Capital Partners
New York
|
-$16M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$9.95M |
| 3 |
Iconiq Capital
San Francisco,
California
|
-$6.72M |
| 4 |
Marshall Wace North America
New York
|
-$941K |
| 5 |
Blackstone Inc
New York
|
-$440K |
VIR Hedge Fund Activity: Q1 2020 in Review
61 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2020, worth a combined $1.3B — up 182% from $460M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new VIR positions and 6 closed out — a net gain of 23 holders — while 15 added to existing stakes and 10 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $7.27M. The largest seller was Indus Capital Partners, cutting an estimated $16M.
- 61 institutional investors held Vir Biotechnology (VIR) as of Q1 2020, up from 38 in Q4 2019.
- Funds reported $1.3B of Vir Biotechnology stock for Q1 2020, up 182% quarter-over-quarter.
- 29 funds opened new Vir Biotechnology positions in Q1 2020 and 6 closed out, a net change of +23 holders.
- The largest Vir Biotechnology buyer in Q1 2020 was EcoR1 Capital, an estimated $7.27M added.
- The largest Vir Biotechnology seller in Q1 2020 was Indus Capital Partners, an estimated $16M sold.
Based on aggregated 13F filings for Q1 2020.